NIRUPAMA SABNIS, PHD, MPH Senior Research Specialist Department of Physiology and Anatomy Lipoprotein Drug Delivery Laboratory UNT Health Science Center, Fort Worth, TX 76107 Email · [email protected]

Research Interests: Targeted drug and nucleic acid delivery, Nanomedicine and Cancer Theranostics translational research, Development of targeted immunotherapy.

WORK EXPERIENCE

2013-present Senior Research specialist, Department of Physiology and Anatomy, UNTHSC, Fort Worth, TX

2012-2013 Director Research Development, Lipomedics Ltd. Fort Worth, TX.

2009-2012 Senior Research Scientist, Dept. of Mol Bio and Immunology, UNTHSC, Fort Worth, TX

2007- 2009 Assistant Director, Datalysis Software, Inc., Fort Worth, TX.

2005-2006 Senior Research Associate. Alcon project, UNT Health Science Center, Fort Worth, TX

1999-2003 Senior Research Associate, UNT Health Science Center, Fort Worth, TX.

1996-1998 Post-Doctoral Research Associate, University of Oklahoma, Norman, OK

1993-1996 Post-Doctoral Research Fellow, UNT Health Science Center, Fort Worth, Tx

1985-1986 Quality Control Manager Flexilens Inc, ,

EDUCATION 2008-2010 MPH, EPIDEMIOLOGY UNT HEALTH SCIENCE CENTER, FORT WORTH, TX

1988-1993 PHD, MICROBIOLOGY INSTITUTE OF CHEMICAL TECHNOLOGY, , INDIA

1983-1986 M.S. MICROBIOLOGY INSTITUTE OF CHEMICAL TECHNOLOGY, UNIVERSITY OF MUMBAI, INDIA

1979-1982 B.S. MICROBIOLOGY, CHEMISTRY RAMNARAIN RUIA COLLEGE, UNIVERSITY OF MUMBAI, INDIA

AWARDS AND HONORS Sept. 2019 Medical Innovator Award, Rutledge Cancer foundation, Fort Worth, TX

1996-1998 Post-doctoral award, Welch foundation.

1993-1995 Post-Doctoral award, National Science Foundation

1992-1994 Technical Advisor, S & S Associates, Mumbai, India

1990-1993 Senior Research fellow, University Grant Foundation, India

1988-1990 Junior Research fellow, University Grant Foundation, India

1977-1979 National merit award, State.

PUBLICATIONS Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles, using Intrinsic Fluorescence. Raut SG, Garud A, Nagarajan B, Sabnis N, Remaley A, Fudala R, Gryczynski I, Gryczynski Z, Dzyuba SV, Borejdo J, Lacko AG. J Pharmacol Exp Ther. 2020 Jan 15. pii: jpet.119.262899. doi: 10.1124/jpet.119.262899.

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9. PMID:31289363

The SR-B1 Receptor as a Potential Target for Treating Glioblastoma. Berney E, Sabnis N, Panchoo M, Raut S, Dickerman R, Lacko AG. J Oncol. 2019 2019:1805841. doi: 10.1155/2019/1805841. eCollection 2019. PMID:31275377

[99mTc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high- density lipoproteins (rHDL) for radioimaging. Isaac-Olivé K, Ocampo-García BE, Aranda-Lara 2 L, Santos-Cuevas CL, Jiménez-Mancilla NP, Luna-Gutiérrez MA, Medina LA, Nagarajan B, Sabnis N, Raut S, Prokai L, Lacko AG. Nanoscale. 2019 Jan 3;11(2):541-551. doi: 10.1039/c8nr07484d. PMID:30543234

SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple- negative breast cancer. Johnson R, Sabnis N, Sun X, Ahluwalia R, Lacko AG. Breast Cancer (Dove Med Press). 2017 9:383-392. doi: 10.2147/BCTT.S131038. eCollection 2017. PMID:28670138

Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery. Sabnis S, Sabnis NA, Raut S, Lacko AG. Int J Nanomedicine. 12:1453-1464. doi: 10.2147/IJN.S122036. eCollection 2017. PMID:28260891

Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Mooberry LK, Sabnis NA, Panchoo M, Nagarajan B, Lacko AG. Front Pharmacol. 2016 Dec 15;7:466. doi: 10.3389/fphar.2016.00466. eCollection 2016. Review. PMID:28018216

Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent. Shah S, Chib R, Raut S, Bermudez J, Sabnis N, Duggal D, Kimball JD, Lacko AG, Gryczynski Z, Gryczynski I.J Photochem Photobiol B. 2016 Feb;155:60-5. doi: 10.1016/j.jphotobiol.2015.12.007. Epub 2015 Dec 18. PMID:26735001

HDL as a drug and nucleic acid delivery vehicle. Lacko AG, Sabnis NA, Nagarajan B, McConathy WJ. Front Pharmacol. 2015 Oct 26;6:247. doi: 10.3389/fphar.2015.00247. eCollection 2015. Review. PMID: 26578957

Targeted nanoparticles for pediatric leukemia therapy. Basha R, Sabnis N, Heym K, Bowman WP, Lacko AG. Front Oncol. 2014 May 13;4:101. doi: 10.3389/fonc.2014.00101. eCollection 2014. Review. PMID: 24860784

Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma. Sabnis N, Pratap S, Akopova I, Bowman PW, Lacko AG. Front Pediatr. 2013 Mar 21;1:6. doi: 10.3389/fped.2013.00006. eCollection 2013 Mar 21. PMID: 24459664

The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Johnson R, Sabnis N, McConathy WJ, Lacko AG. Pharmaceutics. 2013;5(2):353-70. doi: 10.3390/pharmaceutics5020353. PMID: 24244833

The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG. Front Pharmacol. 2013 Sep 25;4:119. doi: 10.3389/fphar.2013.00119. Review. PMID: 24093019

Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Sabnis N, Lacko AG. Ther Deliv. 2012 May;3(5):599-608. Review. Erratum in: Ther Deliv. 2012 Jun;3(6):800.

3 PMID: 22834404

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Sabnis N, Nair M, Israel M, McConathy WJ, Lacko AG. Int J Nanomedicine. 2012;7:975-83. doi: 10.2147/IJN.S28029. Epub 2012 Feb 22. PMID: 22393294

Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Neoplasia. 2011 Apr;13(4):309-19. PMID: 21472135

Studies on solvatochromic properties of aminophenylstyryl-quinolinum dye, LDS 798, and its application in studying submicron lipid based structure. Sarkar P, Luchowski R, Raut S, Sabnis N, Remaley A, Lacko AG, Thamake S, Gryczynski Z, Gryczynski I. Biophys Chem. 2010 Dec;153(1):61-9. doi: 10.1016/j.bpc.2010.10.005. Epub 2010 Oct 13. PMID: 21041016

Cloning and nucleotide sequence of a full-length cDNA encoding Ascaris suum phosphofructokinase. Kulkarni G, Sabnis NA, Bhat KS, Harris BG. J Parasitol. 2005 Jun;91(3):585-90. PMID: 16108551

Cloning, expression, and purification of fumarase from the parasitic nematode Ascaris suum. Kulkarni G, Sabnis NA, Harris BG. Protein Expr Purif. 2004 Feb;33(2):209-13. PMID:14711508

Regulation of Central Carbohydrate Metabolism in Escherichia coli via The Pleiotropic Gene csrA Sabnis, Nirupama; Yang, H. and Romeo, Tony: J. Biol. Chem. 270 (49), 29096-29104, 1995.

PROFESSIONAL AFFILIATIONS: 2012-2016 Member, American Cancer society 2010-2012 Member, Controlled Release Society 2000-2008 Member, American Society of Biochemistry and Molecular Biology 1986-1993 Member, Association of Food Scientists and Technologist, India 1988-1996 Member, Association of Microbiologists of India

Intellectual Property and patents submitted and awarded . Andras Lacko and Nirupama Sabnis. Stabilization of high density lipoprotein nanoparticles. (application # UNTHSC File No. 2020-003, filing date: 12/19/2019). . Sangram Raut, Nirupama Sabnis and Andras Lacko. Optimized Reconstituted High Density Lipoprotein (rHDL) Nanoparticles (NPs) for Therapeutic Drug Delivery and Imaging. (application # UNTHSC File No. 2019-012, filing date: 5/29/2019)

4 . Nirupama Sabnis, Andras Lacko and Alan Remaley. Drug delivery via nanoparticles with myristoyl-5A peptides as basic components; (patent approved: Application number:15/465363, Filing Date: 03/21/2017). . Nirupama Sabnis and Walter McConathy. Enhanced nanoparticle formulation for targeted delivery of valrubicin for the treatment of cancer cells and tumors. (application # 61/862347, Filing Date: 08/05/2013). . Andras Lacko, Nirupama Sabnis, Sunil Shah, Linda Mooberry. Selectively Targeted Doxorubicin Delivery Vehicle Composed of Reconstituted High Density Lipoprotein (rHDL) Nanoparticles. (An Intellectual property disclosure has been filed (UNTHSC International Invention Disclosure/ PCT US2018/028498, updated).

COMMUNITY ACTIVITIES

 Active Member, International society of human values. 2013-present  Advocacy Chair Person. Relay for Life, American Cancer Society. Fort Worth, TX 2009-2016.  Active member. “Art of Living” an international, non-profit, educational and humanitarian organization. 2008- present.  Yoga teacher. For a youth group in Fort Worth, TX since 2011.  Active member of PTA, R.L. Paschal High School, Fort Worth ISD. 2011- present  Reading Coordinator Como Montessori Parent Teachers Association. 2006-2007  A board member Como Montessori Parent Teachers Association, Adopt-A-school Coordinator 2004-06, Reading Coordinator 2006-07. Volunteering in Parent Teacher Association (PTA), Tutoring students in local public schools, assisting teachers in preparing students for Science Fair projects.

5